Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction

Physiology

Volumn 28, Issue 4, 2013, Pages 262-269

  Lasker, George F ^a   Pankey, Edward A ^a   Kadowitz, Philip J ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; CYCLIC GMP; GUANYLATE CYCLASE; MORPHOLINE DERIVATIVE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PYRIMIDINE DERIVATIVE;

ERECTILE DYSFUNCTION; HUMAN; MALE; PATHOPHYSIOLOGY; PENIS ERECTION; PHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

CYCLIC GMP; ERECTILE DYSFUNCTION; GUANYLATE CYCLASE; HUMANS; MALE; MORPHOLINES; NITRIC OXIDE; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84879666580     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00001.2013     Document Type: Review

References (91)

1. Abraham NG, Kappas A. Heme oxygenase and the cardiovascular-renal system. Free Radic Biol Med 39: 1-25, 2005.
2. Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R. Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction. J Androl 27: 335-347, 2006.
3. Ai S, Kuzuya M, Koike T, Asai T, Kanda S, Maeda K, Shibata T, Iguchi A. Rho-Rho kinase is involved in smooth muscle cell migration through myosin light chain phosphorylationdependent and independent pathways. Atherosclerosis 155: 321-327, 2001.
4. Andersson KE. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev 63: 811-859, 2011.
5. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 75: 191-236, 1995.
6. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159: 2164-2171, 1998.
7. Beckman JS, Koppenol WH. Nitric oxide superoxide, peroxynitrite: the good, the bad, the ugly. Am J Physiol Cell Physiol 271: C1424-C1437, 1996.
8. Bellamy TC, Wood J, Garthwaite J. On the activation of soluble guanylyl cyclase by nitric oxide. Proc Natl Acad Sci USA 99: 507-510, 2002.
9. Berner MM, Kriston L, Harms A. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broadspectrum populations. Int J Impot Res 18: 229-235, 2006.
10. Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP. BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology 61: 464-467, 2003.
11. Bivalacqua TJ, Champion HC, Mehta YS, Abdel-Mageed AB, Sikka SC, Ignarro LJ, Kadowitz PJ, Hellstrom WJ. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impot Res 12, Suppl 3: S8-S17, 2000.
12. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, Lewis RL, Mills TM, Hellstrom WJ, Kadowitz PJ. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 101: 9121-9126, 2004.
13. Bivalacqua TJ, Usta MF, Champion HC, Adams D, Namara DB, Abdel-Mageed AB, Kadowitz PJ, Hellstrom WJ. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 169: 1911-1917, 2003.
14. Bivalacqua TJ, Usta MF, Kendirci M, Pradhan L, Alvarez X, Champion HC, Kadowitz PJ, Hellstrom WJ. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med 2: 187-197; discussion 197-188, 2005.
15. Boehning D, Snyder SH. Novel neural modulators. Annu Rev Neurosci 26: 105-131, 2003.
16. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: an orally active type 5 cyclic GMPspecific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8: 47-52, 1996.
17. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78: 257-261, 1996.
18. Brandes RP, Kim D, Schmitz-Winnenthal FH, Amidi M, Godecke A, Mulsch A, Busse R. Increased nitrovasodilator sensitivity in endothelial nitric oxide synthase knockout mice: role of soluble guanylyl cyclase. Hypertension 35: 231-236, 2000.
19. Burnett AL, Johns DG, Kriegsfeld LJ, Klein SL, Calvin DC, Demas GE, Schramm LP, Tonegawa S, Nelson RJ, Snyder SH, Poss KD. Ejaculatory abnormalities in mice with targeted disruption of the gene for heme oxygenase-2. Nat Med 4: 84-87, 1998.
20. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science 257: 401-403, 1992.
21. Burnett AL, Nelson RJ, Calvin DC, Liu JX, Demas GE, Klein SL, Kriegsfeld LJ, Dawson VL, Dawson TM, Snyder SH. Nitric oxide-dependent penile erection in mice lacking neuronal nitric oxide synthase. Mol Med 2: 288-296, 1996.
22. Carati CJ, Creed KE, Keogh EJ. Autonomic control of penile erection in the dog. J Physiol 384: 525-538, 1987.
23. Cavarape A, Endlich N, Assaloni R, Bartoli E, Steinhausen M, Parekh N, Endlich K. Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol 14: 37-45, 2003.
24. Champion HC, Bivalacqua TJ, Hyman AL, Ignarro LJ, Hellstrom WJ, Kadowitz PJ. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci USA 96: 11648-11652, 1999.
25. Chen J, Godschalk MF, Katz PG, Mulligan T. Combining intracavernous injection and external vacuum as treatment for erectile dysfunction. J Urol 153: 1476-1477, 1995.
26. Chitaley K, Bivalacqua TJ, Champion HC, Usta MF, Hellstrom WJ, Mills TM, Webb RC. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem Biophys Res Commun 298: 427-432, 2002.
27. Chitaley K, Webb RC, Mills TM. RhoA/Rho-kinase: a novel player in the regulation of penile erection. Int J Impot Res 13: 67-72, 2001.
28. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, Mills TM. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 7: 119-122, 2001.
29. Coceani F, Breen CA, Lees JG, Falck JR, Olley PM. Further evidence implicating a cytochrome P-450-mediated reaction in the contractile tension of the lamb ductus arteriosus. Circ Res 62: 471-477, 1988.
30. Dai Y, Chitaley K, Webb RC, Lewis RW, Mills TM. Topical application of a Rho-kinase inhibitor in rats causes penile erection. Int J Impot Res 16: 294-298, 2004.
31. Dail WG, Walton G, Olmsted MP. Penile erection in the rat: stimulation of the hypogastric nerve elicits increases in penile pressure after chronic interruption of the sacral parasympathetic outflow. J Auton Nerv Syst 28: 251-257, 1989.
32. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755-768, 2006.
33. Gladwin MT. Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J Clin Invest 116: 2330-2332, 2006.
34. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338: 1397-1404, 1998.
35. Gratzke C, Angulo J, Chitaley K, Dai YT, Kim NN, Paick JS, Simonsen U, Uckert S, Wespes E, Andersson KE, Lue TF, Stief CG. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 7: 445-475, 2010.
36. Gratzke C, Streng T, Waldkirch E, Sigl K, Stief C, Andersson KE, Hedlund P. Transient receptor potential A1 (TRPA1) activity in the human urethra: evidence for a functional role for TRPA1 in the outflow region. Eur Urol 55: 696-704, 2009.
37. Head Clinical Pharmacology, Bayer HealthCare. Multiple dose escalation study (14 days) to investigate safety, tolerability, PK and PD of vardenafil and Bay60-4552. Washington, DC: ClinicalTrials. gov, 2013. [Online: http://www.clinicaltrials.gov/ct2/show/NCT01110590.]
38. Hedlund P, Alm P, Andersson KE. NO synthase in cholinergic nerves and NO-induced relaxation in the rat isolated corpus cavernosum. Br J Pharmacol 127: 349-360, 1999.
39. Hedlund P, Ny L, Alm P, Andersson KE. Cholinergic nerves in human corpus cavernosum and spongiosum contain nitric oxide synthase and heme oxygenase. J Urol 164: 868-875, 2000.
40. Hsieh GC, O'Neill AB, Moreland RB, Sullivan JP, Brioni JD. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur J Pharmacol 458: 183-189, 2003.
41. Hurt KJ, Sezen SF, Lagoda GF, Musicki B, Rameau GA, Snyder SH, Burnett AL. Cyclic AMP-dependent phosphorylation of neuronal nitric oxide synthase mediates penile erection. Proc Natl Acad Sci USA 109: 16624-16629, 2012.
42. Ignarro LJ, Bush PA, Buga GM, Rajfer J. Neurotransmitter identity doubt. Nature 347: 131-132, 1990.
43. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170: 843-850, 1990.
44. Ignarro LJ, Wood KS, Wolin MS. Activation of purified soluble guanylate cyclase by protoporphyrin IX. Proc Natl Acad Sci USA 79: 2870-2873, 1982.
45. Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 79: 958-963, 1997.
46. Keegan A, Cotter MA, Cameron NE. Effects of diabetes and treatment with the antioxidant alpha-lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats. Diabetologia 42: 343-350, 1999.
47. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 84: 4226-4233, 1994.
48. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 47: 457-464, 2000.
49. Lasker GF, Maley JH, Kadowitz PJ. A review of the pathophysiology and novel treatments for erectile dysfunction. Adv Pharmacol Sci 2010: 2010.
50. Lasker GF, Pankey EA, Allain AV, Dhaliwal JS, Stasch JP, Murthy SN, Kadowitz PJ. Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat. J Sex Med 10: 704-718, 2012.
51. Lasker GF, Pankey EA, Allain AV, Murthy SN, Stasch JP, Kadowitz PJ. The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat. Urology 81: 465-467, 2013.
52. Lasker GF, Pankey EA, Frink TJ, Zeitzer JR, Walter KA, Kadowitz PJ. The SGC activator BAY 60-2770 has potent erectile activity in the rat. Am J Physiol Heart Circ Physiol, In press.
53. Lau DH, Kommu S, Mumtaz FH, Morgan RJ, Thompson CS, Mikhailidis DP. The management of phosphodiesterase-5 (PDE5) inhibitor failure. Curr Vasc Pharmacol 4: 89-93, 2006.
54. Lue TF. Erectile dysfunction. N Engl J Med 342: 1802-1813, 2000.
55. Manganiello V. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized. Mol Pharmacol 63: 1209-1211, 2003.
56. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 332: 589-592, 2006.
57. McMahon TJ, Ahearn GS, Moya MP, Gow AJ, Huang YC, Luchsinger BP, Nudelman R, Yan Y, Krichman AD, Bashore TM, Califf RM, Singel DJ, Piantadosi CA, Tapson VF, Stamler JS. A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S-nitrosohemoglobin in pulmonary hypertension. Proc Natl Acad Sci USA 102: 14801-14806, 2005.
58. Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, Wagner K, Matt S, Gegenbauer K, Geschka S, Karas M, Stasch JP, Schmidt HH, Muller-Esterl W. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res 105: 33-41, 2009.
59. Miller LN, Nakane M, Hsieh GC, Chang R, Kolasa T, Moreland RB, Brioni JD. A-350619: a novel activator of soluble guanylyl cyclase. Life Sci 72: 1015-1025, 2003.
60. Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU Int 97: 129-133, 2006.
61. Mizusawa H, Hedlund P, Brioni JD, Sullivan JP, Andersson KE. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J Urol 167: 2276-2281, 2002.
62. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Milbank AJ, Nehra A, Sharlip ID. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol 174: 230-239, 2005.
63. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 10: 69-73; discussion 73-64, 1998.
64. Nunes KP, Webb RC. Mechanisms in Erectile Function and Dysfunction: An Overview, Erectile Dysfunction: Disease-Associated Mechanisms and Novel Insights into Therapy, edited by Nunes K. New York: InTech, 2012. ISBN: 978-953-51-0199-4; DOI: 10.5772/39088. [Available online from: http://www.intechopen.com/books/erectiledysfunction-disease-associated-mechanisms-andnovel-insights-into-therapy/mechanisms-in-erectilefunction-and-dysfunction-an-overview.]
65. Oudot A, Behr-Roussel D, Poirier S, Sandner P, Bernabe J, Alexandre L, Giuliano F. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol 60: 1020-1026, 2011.
66. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY, Place VA, Gesundheit N. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 336: 1-7, 1997.
67. Pankey EA, Bhartiya M, Badejo AM Jr, Haider U, Stasch JP, Murthy SN, Nossaman BD, Kadowitz PJ. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. Am J Physiol Heart Circ Physiol 300: H792-H802, 2011.
68. Qiu X, Villalta J, Lin G, Lue TF. Role of hydrogen sulfide in the physiology of penile erection. J Androl 33: 529-535, 2012.
69. Rajasekaran M, White S, Baquir A, Wilkes N. Rhokinase inhibition improves erectile function in aging male Brown-Norway rats. J Androl 26: 182-188, 2005.
70. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 326: 90-94, 1992.
71. Rees RW, Ralph DJ, Royle M, Moncada S, Cellek S. Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br J Pharmacol 133: 455-458, 2001.
72. Schmidt HH, Schmidt PM, Stasch JP. NO-and haem-independent soluble guanylate cyclase activators. Hand Exp Pharmacol 2009: 309-339, 2009.
73. Schmidt P, Schramm M, Schroder H, Stasch JP. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol 468: 167-174, 2003.
74. Schmidt PM, Schramm M, Schroder H, Wunder F, Stasch JP. Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 279: 3025-3032, 2004.
75. Senbel AM, Hashad A, Sharabi FM, Daabees TT. Activation of muscarinic receptors inhibits neurogenic nitric oxide in the corpus cavernosum. Pharmacol Res 65: 303-311, 2011.
76. Shamloul R. The potential role of the heme oxygenase/carbon monoxide system in male sexual dysfunctions. J Sex Med 6: 324-333, 2009.
77. Shukla N, Hotston M, Persad R, Angelini GD, Jeremy JY. The administration of folic acid improves erectile function and reduces intracavernosal oxidative stress in the diabetic rabbit. BJU Int 103: 98-103, 2009.
78. Spiess PE, Dion SB, Zvara P, Merlin SL, Chan PT, Brock GB. 7-Nitroindazole: a selective inhibitor of penile erection: an in vivo study in a rat animal model. Urology 47: 93-96, 1996.
79. Srilatha B, Adaikan PG, Li L, Moore PK. Hydrogen sulphide: a novel endogenous gasotransmitter facilitates erectile function. J Sex Med 4: 1304-1311, 2007.
80. Stasch JP, Hobbs AJ. NO-independent, haemdependent soluble guanylate cyclase stimulators. Hand Exp Pharmacol 2009: 277-308, 2009.
81. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F. NO-and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136: 773-783, 2002.
82. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY HSA, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561, 2006.
83. Tang C, Li X, Du J. Hydrogen sulfide as a new endogenous gaseous transmitter in the cardiovascular system. Curr Vasc Pharmacol 4: 17-22, 2006.
84. Teixeira CE, Ying Z, Webb RC. Proerectile effects of the Rho-kinase inhibitor (S)-()-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine (H-1152) in the rat penis. J Pharmacol Exp Ther 315: 155-162, 2005.
85. Traish AM, Palmer MS, Goldstein I, Moreland RB. Expression of functional muscarinic acetylcholine receptor subtypes in human corpus cavernosum and in cultured smooth muscle cells. Receptor 5: 159-176, 1995.
86. Wang R. Resurgence of carbon monoxide: an endogenous gaseous vasorelaxing factor. Can J Physiol Pharmacol 76: 1-15, 1998.
87. Weinhold P, Gratzke C, Streng T, Stief C, Andersson KE, Hedlund P. TRPA1 receptor induced relaxation of the human urethra involves TRPV1 and cannabinoid receptor mediated signals, and cyclooxygenase activation. J Urol 183: 2070-2076, 2010.
88. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 80: 629-638, 2002.
89. 2S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am J Physiol Heart Circ Physiol 283: H474-H480, 2002.
90. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J 20: 6008-6016, 2001.
91. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT, Marletta MA. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39: 10848-10854, 2000.